Objective To evaluate the clinical efficacy, pharmacoeconomic value, and potential for reducing antibiotic use of Liushen Capsules in the treatment of acute tonsillitis. Methods A multicenter, prospective cohort study was conducted, enrolling 875 patients with acute tonsillitis (660 in the exposed group, 215 in the non-exposed group). Comparisons were made between the two groups regarding sore throat Visual Analog Scale (VAS) scores, disease recovery rate, efficacy of traditional Chinese medicine (TCM) syndrome differentiation, as well as antibiotic and antipyretic-analgesic usage rates. Pharmacoeconomic evaluation and multivariate logistic regression analysis were also performed. Results After seven days of treatment, the exposed group showed significantly better outcomes than the non-exposed group in terms of reduction in sore throat VAS score, improvement in TCM syndrome recovery rate, and reduction in antibiotic use rate (P<0.05).. Pharmacoeconomic cost-minimizationt analysis indicated that the exposed group was more cost-effective than the non-exposed group. Conclusion Liushen Capsules can effectively alleviate symptoms, improve clinical efficacy, significantly reduce antibiotic use, and demonstrate favorable pharmacoeconomic value in the treatment of acute tonsillitis.

Liushen Capsules  /  acute tonsillitis  /  visual analogue scale  /  pharmacoeconomics  /  Logistic regression analysis